Evidence map›Paper›PMID 42086664›Full record

ArticleNPJ precision oncology2026

Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis.

Binbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, Oluseyi Abidoye, Cody R Eslinger, Yasuyuki Kawamoto, Ryne C Ramaker, Shinji Itoh, Tadayoshi Hashimoto, Takao Fujisawa and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Binbin Zheng-LinEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Taro ShibukiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Heidi E KosiorekDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Oluseyi AbidoyeDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Cody R EslingerDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Ryne C RamakerDepartment of Medicine, Duke University, Durham, NC, USA.
Shinji ItohDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tadayoshi HashimotoDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Takao FujisawaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Mitsuho ImaiDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Angelo PirozziDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Celine HoyekDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Mohamad B SonbolDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Christina WuDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Nguyen H TranDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Hani BabikerDepartment of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Ashley N MoyerDepartment of Pathology, Duke University, Durham, NC, USA.
Yoshiaki NakamuraDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Hideaki BandoDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Takayuki YoshinoDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Daniel H AhnDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
Madhuri GottamDepartment of Medicine, Duke University, Durham, NC, USA.
Mitesh J BoradDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
John H StricklerDepartment of Medicine, Duke University, Durham, NC, USA.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tanios Bekaii-SaabDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA. Bekaii-Saab.Tanios@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of advanced biliary tract cancer remains poor despite up to 40% of tumors harboring actionable molecular alterations. This international collaborative study from Mayo Clinic, Duke Cancer Institute, National Cancer Center East (Japan), and the SCRUM-Japan GOZILA/MONSTAR-SCREEN projects evaluated clinical outcomes in 1049 patients with advanced BTC based on tumor molecular profiling and matched treatment selection. Patients were categorized into non-actionable, actionable with matched targeted therapy (matched), and actionable without matched therapy (unmatched) groups. Among 358 patients (34.1%) with actionable alterations, 160 (44.7%) received matched therapy. The matched group demonstrated significantly longer median overall survival (23.3 months; 95% CI: 19.5-30.4) compared to unmatched (14.7 months; 95% CI: 12.8-17.9) and non-actionable groups (17.1 months; 95% CI: 15.5-18.7; HR 0.57, 95% CI: 0.46-0.71; p 0.0001). In 700 patients receiving ≥2 lines of therapy, matched therapy remained independently associated with improved survival (HR 0.62; 95% CI 0.43-0.90). Notably, patients with actionable tumors who did not receive matched therapy experienced worse outcomes than those with non-actionable disease. These findings highlight the critical need for universal molecular profiling and equitable access to targeted therapies in advanced BTC.

Identifiers

PMID42086664
PMCPMC13350865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.